CommercialCoverageHigh impact
Drug Testing in Pain Management and Substance Use Disorder Treatment (CPB 0965, reviewed 2026-03-03)
Aetna·Pain Management, Psychiatry, Pharmacy·Pharmacy
Effective date
Mar 3, 2026
We identified it
Aug 14, 2026
Summary
Aetna updated its drug testing policy (CPB 0965) for pain management and substance use disorder treatment, establishing strict medical necessity criteria for presumptive and definitive urine drug testing. The policy clarifies which tests are covered, requires individualized testing tied to specific treatment plans, and explicitly designates certain testing methods and broad panels as not medically necessary. Billing teams must immediately audit current drug testing orders to ensure compliance and update billing workflows to reject non-compliant orders.
Action Required
IMMEDIATE (effective 2026-03-03): Billing team must: (1) Update billing system to flag and deny claims for standing/blanket drug test orders (80305, 80306, 80307, 80375, 80376, 80377) unless individual clinical documentation is present; (2) Implement hard stop for simultaneous presumptive and definitive testing for same drugs and same-day dual specimen testing (e.g., blood + urine for same substance); (3) Audit all broad drug test panels currently being billed and cross-reference against member treatment plans — reject claims lacking individualized clinical rationale; (4) Remove coverage for CPT codes 0007U, 0029U, 0031U, 0032U, 0051U in billing software (designated as not medically necessary); (5) Deny all drug testing orders submitted by/on behalf of third parties (courts, employers, schools, insurance verification); (6) Require providers to submit updated treatment plans documenting how drug test results will guide clinical decisions when billing for testing more frequent than weekly; (7) Revise encounter forms and provider alerts to specify that testing must be individualized to member history and clinical presentation, not routine protocols. Failure to enforce these restrictions will result in claim denials and potential recovery audits from Aetna.